These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16464725)

  • 1. Atherosclerosis imaging on the molecular level.
    Bengel FM
    J Nucl Cardiol; 2006; 13(1):111-8. PubMed ID: 16464725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging of plaque vulnerability.
    Tavakoli S; Vashist A; Sadeghi MM
    J Nucl Cardiol; 2014 Dec; 21(6):1112-28; quiz 1129. PubMed ID: 25124827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled Annexin A5.
    Laufer EM; Winkens HM; Corsten MF; Reutelingsperger CP; Narula J; Hofstra L
    Q J Nucl Med Mol Imaging; 2009 Feb; 53(1):26-34. PubMed ID: 19182725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions.
    Hartung D; Schäfers M; Fujimoto S; Levkau B; Narula N; Kopka K; Virmani R; Reutelingsperger C; Hofstra L; Kolodgie FD; Petrov A; Narula J
    Eur J Nucl Med Mol Imaging; 2007 Jun; 34 Suppl 1():S1-8. PubMed ID: 17497106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-FDG imaging of atherosclerosis: will imaging of MMPs assess plaque vulnerability?
    Hermann S; Starsichova A; Waschkau B; Kuhlmann M; Wenning C; Schober O; Schäfers M
    J Nucl Cardiol; 2012 Jun; 19(3):609-17. PubMed ID: 22477642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging of atherosclerosis with integrated PET imaging.
    Hammad B; Evans NR; Rudd JHF; Tawakol A
    J Nucl Cardiol; 2017 Jun; 24(3):938-943. PubMed ID: 28078575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate receptor–targeted single-photon emission computed tomography/computed tomography to detect activated macrophages in atherosclerosis: can it distinguish vulnerable from stable atherosclerotic plaques?
    Winkel LC; Groen HC; van Thiel BS; Müller C; van der Steen AF; Wentzel JJ; de Jong M; Van der Heiden K
    Mol Imaging; 2014; 13():. PubMed ID: 24757762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The progress of nuclear medicine and magnetic resonance molecular imaging of atherosclerotic vulnerable plaques].
    Zhao ZM; Qin SC
    Sheng Li Ke Xue Jin Zhan; 2011 Apr; 42(2):86-90. PubMed ID: 21770253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting P-selectin by gallium-68-labeled fucoidan positron emission tomography for noninvasive characterization of vulnerable plaques: correlation with in vivo 17.6T MRI.
    Li X; Bauer W; Israel I; Kreissl MC; Weirather J; Richter D; Bauer E; Herold V; Jakob P; Buck A; Frantz S; Samnick S
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1661-7. PubMed ID: 24903095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPECT/CT Imaging of High-Risk Atherosclerotic Plaques using Integrin-Binding RGD Dimer Peptides.
    Yoo JS; Lee J; Jung JH; Moon BS; Kim S; Lee BC; Kim SE
    Sci Rep; 2015 Jun; 5():11752. PubMed ID: 26123253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of vulnerable atherosclerosis plaques with a dual-modal single-photon-emission computed tomography/magnetic resonance imaging probe targeting apoptotic macrophages.
    Cheng D; Li X; Zhang C; Tan H; Wang C; Pang L; Shi H
    ACS Appl Mater Interfaces; 2015 Feb; 7(4):2847-55. PubMed ID: 25569777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radionuclide imaging for the detection of inflammation in vulnerable plaques.
    Davies JR; Rudd JH; Weissberg PL; Narula J
    J Am Coll Cardiol; 2006 Apr; 47(8 Suppl):C57-68. PubMed ID: 16631511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies for molecular imaging in the cardiovascular system.
    Khaw BA
    J Nucl Cardiol; 2005; 12(5):591-604. PubMed ID: 16171720
    [No Abstract]   [Full Text] [Related]  

  • 14. MRI, the technology for imaging of thrombi and inflammation.
    von Zur Muhlen C; Bode C
    Hamostaseologie; 2015; 35(3):252-62. PubMed ID: 25634650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-Modality Activity-Based Probes as Molecular Imaging Agents for Vascular Inflammation.
    Withana NP; Saito T; Ma X; Garland M; Liu C; Kosuge H; Amsallem M; Verdoes M; Ofori LO; Fischbein M; Arakawa M; Cheng Z; McConnell MV; Bogyo M
    J Nucl Med; 2016 Oct; 57(10):1583-1590. PubMed ID: 27199363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Where is the trace? Molecular imaging of vulnerable atherosclerotic plaques.
    Langer H; Schönberger T; Bigalke B; Gawaz M
    Semin Thromb Hemost; 2007 Mar; 33(2):151-8. PubMed ID: 17340463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotracer imaging of atherosclerotic plaque biology.
    Elkhawad M; Rudd JH
    Cardiol Clin; 2009 May; 27(2):345-54, Table of Contents. PubMed ID: 19306774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment.
    Arbab-Zadeh A; Fuster V
    J Am Coll Cardiol; 2015 Mar; 65(8):846-855. PubMed ID: 25601032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular imaging of atherosclerotic lesions by positron emission tomography - can it meet the expectations?
    Brammen L; Steiner S; Berent R; Sinzinger H
    Vasa; 2016; 45(2):125-32. PubMed ID: 27058798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [¹⁸F]-fluorodeoxyglucose PET imaging of atherosclerosis.
    Blomberg BA; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):1-7. PubMed ID: 25455876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.